Interleukin-18 system plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions

British Journal of Dermatology

Volumn 166, Issue 6, 2012, Pages 1275-1288

  Do, D V ^a   Ong, C T ^a   Khoo, Y T ^a   Carbone, A ^c,d   Lim, C P ^e   Wang, S ^a   Mukhopadhyay, A ^a   Cao, X ^e   Cho, D H ^f   Wei, X Q ^g   Bellone, G ^c   Lim, I ^a   Phan, T T ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF TURIN   (Italy)

^d MOLINETTE HOSPITAL   (Italy)

^e INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^f Sookmyung Women's University   (South Korea)

^g CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3',3' N XYLENYLBIS(DAUNORUBICIN); 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CASPASE 3; COLLAGEN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 18 RECEPTOR ALPHA; INTERLEUKIN 18 RECEPTOR BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; INTERLEUKIN 8; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOXANTRONE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; TRANSCRIPTION FACTOR SP1;

ARTICLE; CELL LEVEL; COCULTURE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; KELOID; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; WESTERN BLOTTING;

CASPASE 1; CASPASE 3; CELLS, CULTURED; COLLAGEN; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HUMANS; INTERLEUKIN-18; INTERLEUKIN-6; INTERLEUKIN-8; KELOID; KERATINOCYTES; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTORS, INTERLEUKIN-18; SP1 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 84861644267     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10721.x     Document Type: Article

References (51)

1. Louw L,. The keloid phenomenon: progress toward a solution. Clin Anat 2007; 20: 3-14.
2. Lim IJ, Phan TT, Song C, et al. Investigation of the influence of keloid-derived keratinocytes on fibroblast growth and proliferation in vitro. Plast Reconstr Surg 2001; 107: 797-808.
3. Lim IJ, Phan TT, Bay BH, et al. Fibroblasts co-cultured with keloid keratinocytes, normal fibroblasts secrete collagen in a keloid like manner. Am J Physiol Cell Physiol 2002; 283: C212-22.
4. Funayama E, Chodon T, Oyama A, Sugihara T,. Keratinocytes promote proliferation and inhibit apoptosis of the underlying fibroblasts, an important role in the pathogenesis of keloid. J Invest Dermatol 2003; 121: 1326-31.
5. Phan TT, Lim IJ, Bay BH, et al. Role of IGF system of mitogens in the induction of fibroblast proliferation by keloid-derived keratinocytes in vitro. Am J Physiol Cell Physiol 2003; 284: C860-9.
6. Lim IJ, Phan TT, Tan EK, et al. Synchronous activation of ERK and phosphatidylinositol 3-kinase pathways is required for collagen and extracellular matrix production in keloids. J Biol Chem 2003; 278: 40851-8.
7. Xia W, Phan TT, Lim IJ, et al. Complex epithelial-mesenchymal interactions modulate transforming growth factor-beta expression in keloid-derived cells. Wound Repair Regen 2004; 12: 546-56.
8. Mukhopadhyay A, Tan EK, Khoo YT, et al. Conditioned medium from keloid keratinocyte/keloid fibroblast co-culture induces contraction of fibroblast-populated collagen lattices. Br J Dermatol 2005; 152: 639-45.
9. Phan TT, Lim IJ, Aalami O, et al. Smad3 signalling plays an important role in keloid pathogenesis via epithelial-mesenchymal interactions. J Pathol 2005; 20: 232-42.
10. Ong CT, Khoo YT, Tan EK, et al. Epithelial-mesenchymal interactions in keloid pathogenesis modulate vascular endothelial growth factor expression and secretion. J Pathol 2007; 211: 95-108.
11. Khoo YT, Ong CT, Mukhopadhyay A, et al. Upregulation of secretory connective tissue growth factor (CTGF) in keratinocyte-fibroblast coculture contributes to keloid pathogenesis. J Cell Physiol 2006; 208: 336-43.
12. Mukhopadhyay A, Chan SY, Lim IJ, et al. The role of the activin system in keloid pathogenesis. Am J Physiol Cell Physiol 2007; 292: C1331-8.
13. Akita K, Ohtsuki T, Nukada Y, et al. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells. J Biol Chem 1997; 272: 26595-603.
14. Vidal-Vanaclocha F, Mendoza L, Telleria N, et al. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev 2006; 25: 417-34.
15. Debets R, Timans JC, Churakowa T, et al. IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol 2000; 165: 4950-6.
16. Novick D, Kim SH, Fantuzzi G, et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity 1999; 10: 127-36.
17. Kämpfer H, Kalina U, Mühl H, et al. Counterregulation of interleukin-18 mRNA and protein expression during cutaneous wound repair in mice [Comment]. J Invest Dermatol 1999; 114: 598-9.
18. Kämpfer H, Paulukat J, Mühl H, et al. Lack of interferon-gamma production despite the presence of interleukin-18 during cutaneous wound healing. Mol Med 2000; 6: 1016-27.
19. Gracie JA, Forsey RJ, Chan WL, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest 1999; 104: 1393-401.
20. Kawashima M, Yamamura M, Taniai M, et al. Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001; 44: 550-60.
21. Ohta Y, Hamada Y, Katsuoka K,. Expression of IL-18 in psoriasis. Arch Dermatol Res 2001; 293: 334-42.
22. Mallat Z, Corbaz A, Scoazec A, et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-5.
23. Ludwiczek O, Kaser A, Novick D, et al. Plasma levels of interleukin-18 and interleukin-18 binding protein are elevated in patients with chronic liver disease. J Clin Immunol 2002; 22: 331-7.
24. Kitasato Y, Hoshino T, Okamoto M, et al. Enhanced expression of interleukin-18 and its receptor in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2004; 31: 619-25.
25. Wei XQ, Leung BP, Arthur HM, et al. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18. J Immunol 2001; 166: 517-21.
26. Whitman SC, Ravisankar P, Daugherty A,. Interleukin-18 enhances atherosclerosis in apolipoprotein E-/- mice through release of interferon-gamma. Circ Res 2002; 90: E34-8.
27. Mallat Z, Corbaz A, Scoazec A, et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
28. Elhage R, Jawien J, Rudling M, et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003; 59: 234-40.
29. Cho D, Song H, Kim YM, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res 2000; 60: 2703-9.
30. Majima T, Ichikura T, Chochi K, et al. Exploitation of interleukin-18 by gastric cancers for their growth and evasion of host immunity. Int J Cancer 2006; 118: 388-95.
31. Telleria N, Carrascal T, Beaskoetxea J, et al. Interleukin-18 upregulates very late antigen-4 expression from melanoma cell variants of low intracellular glutathione content, via oxidative stress-induced autocrine tumor necrosis factor-alpha. Cancer Res 2006; 66: 10497-504.
32. Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 2007; 26: 1468-76.
33. Carbone A, Rodeck U, Mauri FA, et al. Human pancreatic carcinoma cells secrete bioactive interleukin-18 after treatment with 5-fluorouracil: implications for anti-tumor immune response. Cancer Biol Ther 2005; 4: 231-41.
34. Novick D, Schwartsburd B, Pinkus R, et al. A novel IL-18BP ELISA shows elevated serum IL-18BP in sepsis and extensive decrease of free IL-18. Cytokine 2001; 14: 334-42.
35. Marshall JD, Aste-Amezaga M, Chehimi SS, et al. Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90: 15-21.
36. Koizumi H, Sato-Matsumura KC, Nakamura H, et al. Distribution of IL-18 and IL-18 receptor in human skin: various forms of IL-18 are produced in keratinocytes. Arch Dermatol Res 2001; 293: 325-33.
37. Park H, Byun D, Kim TS, et al. Enhanced IL-18 expression in common skin tumors. Immunol Lett 2001; 79: 215-19.
38. Scott MJ, Hoth JJ, Gardner SA, et al. Genetic background influences natural killer cell activation during bacterial peritonitis in mice, and is interleukin 12 and interleukin 18 independent. Cytokine 2004; 28: 124-36.
39. Naik SM, Cannon G, Burbach GJ, et al. Human keratinocytes constitutively express interleukin-18 and secrete biologically active interleukin-18 after treatment with pro-inflammatory mediators and dinitrochlorobenzene. J Invest Dermatol 1999; 113: 766-72.
40. Akasaka Y, Ito K, Fujita K, et al. Activated caspase expression and apoptosis increase in keloids: cytochrome c release and caspase-9 activation during the apoptosis of keloid fibroblast lines. Wound Repair Regen 2005; 13: 373-82.
41. Lonnemann G, Novick D, Rubinstein M, Dinarello CA,. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol 2003; 60: 327-34.
42. Kawashima M, Novick D, Rubinstein M, Miossec P,. Regulation of interleukin-18 binding protein production by blood and synovial cells from patients with rheumatoid arthritis. Arthritis Rheum 2004; 50: 1800-5.
43. Mallat Z, Heymes C, Corbaz A, et al. Evidence for altered interleukin (IL)-18 pathway in human heart failure. FASEB J 2004; 18: 1752-4.
44. Mazodier K, Marin V, Novick D, et al. Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. Blood 2005; 106: 3483-9.
45. Plater-Zyberk C, Joosten LA, Helsen MM, et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 2001; 108: 1825-32.
46. Banda NK, Vondracek A, Kraus D, et al. Mechanisms of inhibition of collagen-induced arthritis by murine IL-18 binding protein. J Immunol 2003; 170: 2100-5.
47. Carrascal MT, Mendoza L, Valcárcel M, et al. Interleukin-18 binding protein reduces b16 melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium. Cancer Res 2003; 63: 491-7.
48. Wang Y, Li C, Wang X, et al. Heat shock response inhibits IL-18 expression through the JNK pathway in murine peritoneal macrophages. Biochem Biophys Res Commun 2002; 296: 742-8.
49. Chandrasekar B, Marelli-Berg FM, Tone M, et al. Beta-adrenergic stimulation induces interleukin-18 expression via beta2-AR, PI3K, Akt, IKK, and NF-kappaB. Biochem Biophys Res Commun 2004; 319: 304-11.
50. Park HJ, Kim HJ, Lee JH, et al. Corticotropin-releasing hormone (CRH) downregulates interleukin-18 expression in human HaCaT keratinocytes by activation of p38 mitogen-activated protein kinase (MAPK) pathway. J Invest Dermatol 2005; 124: 751-5.
51. Niyonsaba F, Ushio H, Nagaoka I, et al. The human beta-defensins (-1, -2, -3, -4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J Immunol 2005; 175: 1776-84.